Aureon Laboratories to Collaborate with UCSF on Research Study to Construct Predictive Models for GM-CSF Treatment Response in Patients with Prostate Cancer.

YONKERS, N.Y. -- Aureon Laboratories, Inc. announced today a research collaboration with the University of California, San Francisco (UCSF) to retrospectively analyze a Phase I clinical trial that examined the effects of neoadjuvant treatment with granulocyte macrophage colony stimulating factor (GM-CSF) prior to radical prostatectomy.

The goal of the study will be to use Aureon's Systems Pathology platform to identify histological, molecular, and clinical phenotypes within patient samples both pre and post treatment in order to construct models that assist in predicting therapeutic response. Aureon's approach includes morphometric image analysis of histological specimens and cell-type specific, multiplexed molecular biomarkers. This information is integrated with clinical data using multivariate analysis and associated with clinical endpoints of interest.

Vijay Aggarwal, PhD, CEO and President of Aureon Laboratories said, "We are very excited about collaborating with UCSF on this research project. Aureon is developing Prostate Px+, a prognostic test to assist men who are recently diagnosed with prostate cancer and need more accurate information prior to treatment. Now, Aureon's powerful technology platform will be used, in a complementary way to assist research that may have implications for prostate cancer vaccine development." Dr. Aggarwal added, "Ultimately, Aureon's primary goal is to provide more information for men who are diagnosed with prostate cancer."

About Aureon Laboratories

Aureon Laboratories' mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput Systems Pathology technology platform to predict individual clinical outcomes through the interrogation of tissue and is the basis for the Prostate Px+ test which will provide physicians and patients with a unique insight into the likelihood of prostate cancer recurrence and progression at the time of biopsy and diagnosis. For more information about Aureon or Prostate Px+, go to www.aureon.com or call 1-888-SYS-PATH.

NOTE: Prostate Px, Prostate Px+ and Px SCORE are registered trademarks of Aureon Laboratories, Inc.